Endometriosis — what's actually happening at the lesion level

You have probably been told, at some point, that this is just how periods are. Or that your pain tolerance is low. Or that things will improve after pregnancy. The average diagnostic delay for endometriosis is seven to ten years. That number is repeated often enough that it has become a statistic, which makes it easier to receive as information than as what it actually is: seven to ten years of a person's life spent with a condition that is physically painful, functionally limiting, and emotionally wearing, being told that their experience is normal or exaggerated. The delay is a failure of how medicine has been trained to take women's pelvic pain seriously. It is not a reflection of how subtle endometriosis is.

Here is what endometriosis actually is and what is happening at the tissue level.

Endometriosis is a condition in which tissue that shares characteristics with the endometrium — the lining of the uterus — grows outside the uterus. The most common sites are the ovaries, the peritoneum (the lining of the pelvic cavity), the fallopian tubes, the uterosacral ligaments, and the space between the uterus and rectum called the pouch of Douglas. In severe cases — deeply infiltrating endometriosis — lesions penetrate deeper into structures: into the bowel, the bladder, the ureter, the diaphragm. The lesions are not simply misplaced endometrial cells. They are distinct lesions that have established their own blood supply, their own nerve innervation, and their own local inflammatory environment. They respond, to varying degrees, to the cyclical hormonal fluctuations of the menstrual cycle — estrogen drives them to grow, and they bleed locally with each cycle, causing the progressive inflammation and scarring that produces adhesions over time.

The inflammation is central. Each lesion is surrounded by a microenvironment of elevated prostaglandins, cytokines, and inflammatory mediators — interleukin-1, interleukin-6, TNF-alpha — that sensitize local nerve endings and contribute to both the peripheral pain experience and, over time, central sensitization. This is why endometriosis pain often feels disproportionate to what any imaging can show: the pain system itself becomes sensitized through chronic inflammatory exposure, and the central nervous system learns to interpret pelvic input as painful in ways that persist even when disease burden is reduced. Adhesions — fibrous tissue formed as the body attempts to wall off repeated local injury — create structural distortion: organs adhere to one another, movement causes pulling and tearing sensations, normal bowel motility through adhesion-involved loops of intestine becomes painful. The GI symptoms that many women with endometriosis experience — bloating, irregular bowel habits, pain with bowel movements, sometimes nausea — are not coincidental. They can reflect direct bowel involvement, but they also reflect the shared neural and inflammatory architecture of the pelvic cavity, as well as the high rate of IBS comorbidity in endo patients.

Neoangiogenesis — the formation of new blood vessels to supply the lesions — is part of why lesions persist and expand. VEGF (vascular endothelial growth factor) is elevated in the peritoneal fluid of women with endometriosis. The lesions recruit vascular supply from the host tissue, making them metabolically independent in a way that allows them to survive despite the hostile inflammatory environment they create. This is also part of why endometriosis returns after surgical removal if excision is incomplete — residual lesions retain their blood supply and the hormonal responsiveness to continue cycling and growing.

Conventional management of endometriosis follows a hierarchy based on disease severity, fertility goals, and symptom burden. NSAIDs are first-line for pain management — they work by blocking prostaglandin synthesis and are most effective when started before the period begins, at the onset of inflammation rather than after it's fully established. Combined oral contraceptives suppress the cyclical hormonal fluctuations that drive lesion activity and reduce menstrual flow; continuous dosing can eliminate cycles entirely, which reduces the repeated inflammatory insult. Progestins — norethindrone, dienogest, medroxyprogesterone — suppress estrogen-driven lesion growth and are often used continuously for this purpose. GnRH agonists create a state of medical menopause by suppressing ovarian estrogen production entirely; they are highly effective at reducing lesion activity but carry significant side effects and bone density loss with extended use, making them better suited for shorter courses or with hormonal add-back therapy. GnRH antagonists offer similar suppression with a more manageable titration. Hormonal therapies suppress endometriosis activity but do not remove the lesions; they are managing a chronic disease, not treating it structurally.

Surgery — specifically, excision surgery — remains the most definitive approach to reducing disease burden. Excision means cutting out lesions at the root rather than ablating (burning) their surface; it is technically demanding and outcome-dependent on surgeon expertise. The evidence for excision over ablation is consistent: excision has lower recurrence rates, higher patient-reported symptom improvement, and better outcomes for the deeply infiltrating disease that ablation cannot adequately address. Finding a surgeon with dedicated endometriosis expertise matters enormously. The difference in outcomes between a general OB-GYN doing laparoscopy and an endometriosis specialist performing thorough excision is not a minor variation; it is the primary driver of whether surgery helps long-term or leads to another surgery in two years. Minimally invasive gynecologic surgery (MIGS) specialists with endometriosis subspecialization represent the current standard for surgical care.

The peptide conversation in endometriosis is adjacent and supportive rather than central. Endometriosis is a structural disease with systemic inflammatory features, and peptide research in this space reflects that reality. BPC-157, a body-protective compound derived from a gastric pentadecapeptide sequence, has been extensively researched in animal models for its roles in tissue healing, gut mucosal repair, and inflammatory modulation. Given the significant GI comorbidity in endometriosis — the gut involvement both direct (bowel lesions) and indirect (visceral hypersensitivity, IBS overlap, post-excision adhesion-related motility issues) — the gut-protective research profile of BPC-157 is potentially relevant. BPC-157 research in animal models has demonstrated anti-inflammatory effects through multiple pathways, including effects on the NO system and on inflammatory cytokine production. The clinical evidence in humans is limited and BPC-157 is not an approved treatment; these are research-stage observations that belong in a provider conversation, not self-directed intervention.

KPV — a tripeptide fragment of alpha-MSH (Lys-Pro-Val) — has been researched for its anti-inflammatory properties, particularly its ability to modulate the NF-kB inflammatory pathway and reduce cytokine production including TNF-alpha and IL-6. In the context of endometriosis, where elevated inflammatory cytokines are central to lesion maintenance and pain sensitization, the anti-inflammatory research profile of KPV is mechanistically interesting. VIP — vasoactive intestinal peptide — has been researched for its role in immune modulation and its anti-inflammatory effects in inflammatory bowel conditions; given the GI and inflammatory overlap in endometriosis, it occupies an adjacent research space. Both remain research-stage rather than clinically established for endometriosis specifically.

Cetrorelix, worth noting, is itself a GnRH antagonist — meaning it is part of the conventional hormonal management toolkit for endometriosis, not a novel peptide intervention. It is used in assisted reproductive technology protocols and in some endometriosis management contexts as part of suppression therapy. Including it in the peptide conversation is accurate but the important context is that it operates at the conventional hormonal management level, not as an adjunctive or experimental intervention.

The honest framing here is unambiguous: endometriosis is a structural, surgical, and hormonally mediated disease that requires specialist medical management. Peptide approaches, to the extent they have any role, are adjunctive to — not replacements for — that management. The inflammatory burden, the adhesion formation, the bowel involvement, the infertility implications all require appropriate specialist evaluation and ongoing management by gynecologists and endometriosis surgeons who understand the full picture of the disease.

Pelvic floor physical therapy deserves specific mention because it is underutilized and specifically helpful. The chronic pain of endometriosis — and the guarding, the bracing, the protective movement patterns the body develops over years of pain — creates pelvic floor dysfunction that persists even after the disease is treated. Pain with sex, pelvic floor tightness, difficulty with penetration, and changes in bowel and bladder function often have a pelvic floor component that can be meaningfully addressed with skilled PT. It is not a substitute for surgical or hormonal management; it is a component of comprehensive pain management that addresses what happens to the soft tissue and neuromuscular system during years of living with pelvic pain.

The diagnostic delay is the largest structural problem in endometriosis care. Seven to ten years is a long time to spend discounting an experience that is real, physiological, and treatable. If you are managing cyclical or chronic pelvic pain that feels outside the range of ordinary period experience — pain that alters your plans, pain with sex, bowel symptoms that track with your cycle, pain that doesn't respond to standard NSAIDs — finding a gynecologist who takes endometriosis seriously and pursues a thorough evaluation is not optional. Laparoscopy remains the definitive diagnostic standard, though skilled clinical evaluation with ultrasound by a sonographer experienced in endometriosis can identify ovarian endometriomas and some deep infiltrating disease. The diagnosis requires someone who is looking for it. The treatment requires someone who knows how to manage it. Both matter, and you deserve to be in the hands of both.